+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Hemophilia"

Hemophilia Global Market Report 2024 - Product Thumbnail Image

Hemophilia Global Market Report 2024

  • Report
  • January 2024
  • 175 Pages
  • Global
From
From
From
From
Hematology Collaboration and Licensing Deals 2016-2024 - Product Thumbnail Image

Hematology Collaboration and Licensing Deals 2016-2024

  • Report
  • April 2024
  • 100 Pages
  • Global
From
From
From
Rare Hemophilia Factors - Global Strategic Business Report - Product Thumbnail Image

Rare Hemophilia Factors - Global Strategic Business Report

  • Report
  • April 2024
  • 93 Pages
  • Global
From
From
Blood Plasma Derivatives Global Market Report 2024 - Product Thumbnail Image

Blood Plasma Derivatives Global Market Report 2024

  • Report
  • February 2024
  • 175 Pages
  • Global
From
Thrombophilia Global Market Report 2024 - Product Thumbnail Image

Thrombophilia Global Market Report 2024

  • Report
  • January 2024
  • 200 Pages
  • Global
From
Bleeding Disorders Treatment Global Market Report 2024 - Product Thumbnail Image

Bleeding Disorders Treatment Global Market Report 2024

  • Report
  • December 2023
  • 200 Pages
  • Global
From
Loading Indicator

Hemophilia is a rare, inherited bleeding disorder in which the blood does not clot properly. People with hemophilia lack certain proteins, called clotting factors, which are necessary for normal blood clotting. Without these clotting factors, even a minor injury can cause excessive bleeding. Hemophilia is classified into two main types, hemophilia A and hemophilia B, depending on the clotting factor that is missing. The hemophilia market is a subset of the hematology market, which includes treatments for a variety of blood-related disorders. The hemophilia market is composed of treatments for hemophilia A and B, such as recombinant clotting factors, gene therapy, and other treatments. These treatments are used to reduce the frequency and severity of bleeding episodes, as well as to prevent bleeding in the first place. Some companies in the hemophilia market include Novo Nordisk, Pfizer, Shire, Bayer, and CSL Behring. Show Less Read more